Chapter 13. Tumor Vaccination after Autologous HSCT: What has been Learned from Experimental Models
- Rimas Orentas PhD1,
- James W. Hodge PhD2,
- Bryon D. Johnson PhD3
Published Online: 1 MAR 2007
DOI: 10.1002/9780470170113.ch13
Copyright © 2008 John Wiley & Sons, Inc.
Book Title
Cancer Vaccines and Tumor Immunity
Additional Information
How to Cite
Jing, W. and Johnson, B. D. (2007) Tumor Vaccination after Autologous HSCT: What has been Learned from Experimental Models, in Cancer Vaccines and Tumor Immunity (eds R. Orentas, J. W. Hodge and B. D. Johnson), John Wiley & Sons, Inc., Hoboken, NJ, USA. doi: 10.1002/9780470170113.ch13
Editor Information
- 1
Departments of Pediatrics, Medicine, Microbiology and Molecular Genetics, Medical College of Wisconsin and the Children's Research Institute, Children's Hospital of Wisconsin, Milwaukee, WI, USA
- 2
Department of Medical Biology, University of Tennessee Medical Center and Laboratory of Tumor Immunology and Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
- 3
Department of Pediatrics, Medical College of Wisconsin and the Children's Research Institute, Children's Hospital of Wisconsin., Milwaukee, WI, USA
Publication History
- Published Online: 1 MAR 2007
- Published Print: 22 JAN 2008
ISBN Information
Print ISBN: 9780470074749
Online ISBN: 9780470170113
- Summary
- Chapter
Keywords:
- hematopoietic stem cell transplantation (HSCT);
- T cells and early post-HSCT tumor vaccination;
- regulatory T (Treg) cell inhibition and cancer immunotherapy
Summary
This chapter contains sections titled:
Introduction
Animal Models of Autologous HSCT: What we have Learned
Immune Reconstitution
Presence of Immune Regulatory Cells
Tumor Burden
Conclusions and Future Considerations
References